Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

T. Rowe Price Launches Three Active Equity ETFs

BY | ETF Database
9:27 am ET 09/17/26 | 12 VIEWS
T. Rowe Price Group launched three active equity ETFs Thursday. The funds target biotechnology, small-cap and mid-cap stocks, the company said.Key Takeaways T. Rowe Price added three active equity ETFs to its lineup this week. Biotech, small-cap and mid-cap strategies join 35 other active funds at the firm. New expense ratios range from 0.47% to 0.59% across the three ETFs. The three funds push T. Rowe Price’s active ETF lineup to 38 funds. Eight of those launched this year alone, according to the company, giving advisors more choices across three market segments. Tim Coyne, the firm’s global head of ETFs, said the funds “broaden investors’ access to distinct areas of the market.” He said they combine the firm’s research, active management and “the fully transparent ETF structure.” See more: Fed Meeting: How Active ETFs Can Meet the Moment All three ETFs are fully transparent and began trading on the Nasdaq exchange Thursday. They join a T. Rowe Price lineup that spans equity, fixed income, multi-asset and thematic strategies, the firm said. The T. Rowe Price Biotech ETF (TDNA) targets biotech companies that could treat or cure disease, according to the company. Portfolio manager John Hall has 11 years of investment experience at the firm. TDNA aims to hold 60 to 120 stocks, and it charges a 0.55% expense ratio. Diversified exposure to U.S. small-cap stocks is the focus of the T. Rowe Price Small-Cap ETF (TSEE). The fund leans on the firm’s small-cap heritage and fundamental research, T. Rowe Price said. Alex Roik, who has 13 years of investment experience, manages the fund. TSEE typically holds 200 or more stocks and carries a 0.59% expense ratio.Mid-Cap Fund Expands Active Research LineupThe T. Rowe Price Mid-Cap Equity Research ETF (TMID) expands the firm’s Structured Research Strategies lineup, per the company. That lineup also includes the T. Rowe Price Equity Research ETF (TSPA B), T. Rowe Price International Equity Research ETF (TIER ), and T. Rowe Price Emerging Markets Equity Research (TEMR). The firm’s research analysts drive stock selection in TMID through their “best ideas,” according to the company. Paige Davis Jr., Amanda Ludwitzke and Thomas Watson manage the fund. Together, they have a combined 49 years of investing experience. TMID typically holds more than 300 stocks and carries a 0.47% expense ratio, the firm said. T. Rowe Price managed $1.90 trillion in client assets as of August 31, the company reported. Retirement accounts, such as 401(k) plans, account for about two-thirds of that total. For more news, information, and analysis, visit our Active ETF Content Hub.

More Commentary

ETF Prime: Record Inflows and the First TXSE ETF Launch
BY | ETF Database
10:13 am ET 09/17/26 | 15 VIEWS
Commodities Supercycle Could Make This ETF Super
BY | ETF Database
7:04 am ET 09/17/26 | 46 VIEWS
Rate Hike Brings Opportunity With This Bond ETF
BY | ETF Database
6:14 am ET 09/17/26 | 37 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.